Prednisolone pharmacokinetics in dogs with protein-losing enteropathy
Journal of Veterinary Internal Medicine · 2025
DOI: 10.1111/jvim.17277 ↗At a glance
Journal article in Journal of Veterinary Internal Medicine, 2025. Written by Sara A Jablonski and 4 co-authors. Institution: Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, USA. Major MEDLINE topics: Protein-Losing Enteropathies, Prednisolone, Dog Diseases. Cited 6 times so far (Crossref); 53 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Michigan State University College of Veterinary Medicine Endowed Research Funds, Specifically the Della K. Swander Fund, Michigan State University College of Veterinary Medicine Trinket Fund.
Abstract (original language)
Background
It is unknown if glucocorticoid malabsorption contributes to the approximate 50% treatment failure rate in dogs with protein-losing enteropathy (PLE).
Objective
To compare pharmacokinetics (PK) of orally administered prednisolone in dogs with PLE vs healthy controls. Animals Fourteen dogs with well-characterized PLE and 7 control dogs.
Methods
Prospective case-controlled study. Dogs were treated with 1 mg/kg prednisolone PO once daily for approximately 3 weeks. Venous blood samples were collected at set timepoints before and after prednisolone administration on the first (T1) and final (T2) study days. Total and non-protein bound serum prednisolone concentrations were determined using liquid chromatography tandem-mass spectrometry, and pharmacokinetics variables were derived from the drug concentration data. Pharmacokinetics variables were compared between PLE and control dogs and between PLE short-term responders and non-responders.
Results
The PLE dogs had a shorter half-life of the terminal slope than control dogs (harmonic mean of 1.3 vs 1.8 hours; P = .05) whereas the percentage of serum prednisolone that was non-protein bound was higher in PLE dogs than in control dogs (median of 15.7% vs 6.7%; P = .02) at T1. Total prednisolone drug exposures and maximum total serum drug concentrations did not differ between PLE and control dogs at T1 or T2, nor did they differ between short-term responders and non-responders within the PLE population (P > .05 for all comparisons). Conclusions and Clinical Importance Overall drug exposures are similar between PLE dogs and healthy controls. Glucocorticoid malabsorption is unlikely to be a common cause of treatment failure in dogs with PLE.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, USA.
- Department of Pathobiology and Diagnostic Investigation, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, USA.
- Veterinary Diagnostic Laboratory, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, USA.
ORCID profiles: Sara A Jablonski, Daniel K Langlois
Funding
- Michigan State University College of Veterinary Medicine Endowed Research Funds, Specifically the Della K. Swander Fund
- Michigan State University College of Veterinary Medicine Trinket Fund
Cite
APA
Jablonski, S. A., Strohmeyer, J. L., Buchweitz, J. P., Lehner, A. F., & Langlois, D. K. (2025). Prednisolone pharmacokinetics in dogs with protein-losing enteropathy. Journal of Veterinary Internal Medicine. https://doi.org/10.1111/jvim.17277
Vancouver
Jablonski SA, Strohmeyer JL, Buchweitz JP, Lehner AF, Langlois DK. Prednisolone pharmacokinetics in dogs with protein-losing enteropathy. Journal of Veterinary Internal Medicine. 2025. doi:10.1111/jvim.17277
BibTeX
@article{Jablonski2025,
author = {Jablonski, Sara A and Strohmeyer, Jessica L and Buchweitz, John P and Lehner, Andreas F and Langlois, Daniel K},
title = {Prednisolone pharmacokinetics in dogs with protein-losing enteropathy},
journal = {Journal of Veterinary Internal Medicine},
year = {2025},
doi = {10.1111/jvim.17277}
}
EUVIMED